SAN JOSE, Calif. / Nov 09, 2023 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences. Outset will participate in the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, and the Jefferies London Healthcare Conference on Thursday, November 16, 2023.
Event: Stifel 2023 Healthcare Conference
Date: Tuesday, November 14, 2023
Time: 9:45am ET
Event: Jefferies London Healthcare Conference
Date: Thursday, November 16, 2022
Time: 6:30am ET / 11:30am GMT
Live and archived webcasts of the fireside chats will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Last Trade: | US$13.35 |
Daily Change: | -0.37 -2.70 |
Daily Volume: | 117,491 |
Market Cap: | US$237.230M |
September 03, 2025 August 20, 2025 August 06, 2025 June 05, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load